Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fluoroquinolones

FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2019

The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…

Filed under:AnalgesicsDrug Updates Tagged with:bupivacaineFDAfluoroquinolonesHTX-011meloxicamsafety warningU.S. Food and Drug Administration (FDA)

Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination

Michele B. Kaufman, PharmD, BCGP  |  July 12, 2016

FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…

Filed under:AnalgesicsDrug Updates Tagged with:acetaminophenanalgesicantibioticsbenzhydrocodonedrugFDAfluoroquinolonespatient careRheumatic DiseaserheumatologySafetytherapyTreatment

FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain

Michele B. Kaufman, PharmD, BCGP  |  June 1, 2016

The FDA has issued new safety guidelines for systemic fluoroquinolones, restricting their use to patients with no alternative treatment options…

Filed under:AnalgesicsDrug Updates Tagged with:acetaminophenBenzhydrocodone hydrochlorideDrug SafetyFDAFood and Drug AdministrationPainsafety warningside effect

What’s New in Large Vessel Vasculitis

Philip Seo, MD, MHS  |  August 7, 2024

The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…

Filed under:ConditionsGuidanceResearch ReviewsResearch RheumVasculitis Tagged with:diverticulitisgastrointestinal perforationGiant Cell Arteritisgiant cell arteritis (GCA)interleukin-17A inhibitorlarge-vessel vasculitisTakayasu arteritis (TAK)Takayasu’s Arteritistocilizumab

A Clear Vision: Understanding the Connection Between Ophthalmology & Rheumatic Disease

Jason Liebowitz, MD, FACR  |  August 11, 2022

Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.

Filed under:ConditionsMeeting Reports Tagged with:Annual Advances in the Diagnosis and Treatment of the Rheumatic DiseaseseyesophthalmologyRheumatic DiseaseRheumatoid Arthritis (RA)SarcoidosisUveitis

Case Report: Metoprolol-Induced Arthralgia

Case Report: Metoprolol-Induced Arthralgia

Saba Ziaee, MD, & Zineb Aouhab, MD  |  March 17, 2018

Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect…

Filed under:ConditionsSoft Tissue Pain Tagged with:arthralgiasbeta blockersmetoprolol

Shorter Antibiotic Therapy Effective for Pyogenic Vertebral Osteomyelitis

Lara C. Pullen, PhD  |  January 16, 2015

Six-week treatment regimen returns same results as 12 weeks in recent study, although researchers caution findings may not apply to all patients with vertebral osteomyelitis

Filed under:ConditionsResearch Rheum Tagged with:antibioticspatient caretherapy

Drug Updates: Lorcaserin, Acetaminophen, and More

Michele B. Kaufman, PharmD, BCGP  |  September 5, 2012

information on new approvals and medication safety

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:acetaminophenAnkylosing SpondylitisApprovalsBiologicsdrugFDAPipelinePsoriatic ArthritisrituximabSafetySteroids

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences